The distribution of coexisting subclonal mutations in EGFR, KRAS, and NRAS in fusion-present CRC cases matches genomic profiles of CRC tumors after progression on prior anti-EGFR therapy in tumors initially identified as RAS wild type using a less-sensitive tissue-based assay. This evidence concerns the gene KRAS and colorectal carcinoma.